For research purposes only — These compounds aren't FDA approved. All data presented is from clinical trials for educational reference.
Ipamorelin
GH Secretagogue Peptide
Dosage
Quantity
Price
$44.99
Free shipping on orders $150+
60-day money-back guarantee
Secure checkout
Made in the USA
Certificate of Analysis
Batch verified lab data
99.93%
Purity
- Variant
- Ipamorelin 10mg
- Lot #
- A0112
- Labeled
- 20mg
- Actual
- 22.56mg
- Tested
- Feb 4, 2026
Frequently Researched Together
View allResearch Purposes Snapshot
Ipamorelin is a pentapeptide GHRP-class secretagogue noted for pituitary-selective GH release in animal and early human work. Summaries below draw on Raun et al. (1998), Andersen et al. (2001), Johansen et al. (1999), Beck et al. (2014), and review articles—not FDA approval or dosing guidance for this SKU.
Selective
GH release
At studied doses, GH elevation without meaningful cortisol or prolactin excursions vs legacy GHRPs.
~2 h
Half-life
Human PK studies describe ~2-hour terminal phase—supports intermittent / pulsatile-style dosing discussions.
24%
Bone growth
Dose-dependent rise in longitudinal bone growth rate in growth-plate models vs control (~42→52 µm/day).
87.5%
Tolerability
Phase II POI trial: any-AE rate numerically lower than placebo (94.8%)—mostly mild surgical-context events.
80
ED50 (nmol/kg)
Potency benchmark for GH release in species-specific GHRP assays (Raun et al., 1998).
Development status
Where it stands
- Historical developer
- Novo Nordisk
- Development code
- NNC 26-0161
- Research themes
- GH axis, GI motility / POI
- US status
- Not FDA-approved
Key advantage
Why selectivity matters
First-generation GHRPs (e.g., GHRP-6) release GH but co-secrete ACTH/cortisol and prolactin, driving appetite, fluid retention, and stress-hormone noise. Ipamorelin was designed to preserve GH potency while blunting those off-target axes.
GH release ED50
Cortisol panel
What research has shown
Preclinical potency data plus Phase II surgical tolerability
Preclinical pharmacology
80 nmol/kg ED50 (GH release)
Longitudinal growth (µm/day)
Post-operative ileus cohort
117
Randomized, placebo-controlled patients
GHRP comparison (ED50 scale)
Potency vs GHRP-2 / GHRP-6
Bar width ∝ ED50 (higher nmol/kg = wider bar = less potent on this scale)
Differentiator: only ipamorelin is described as sparing cortisol / ACTH / prolactin / aldosterone surges at GH-equivalent doses in foundational GHRP literature.
Beyond GH release
Applications discussed in reviews and specialty papers
24%
Bone growth
Andersen et al., 2001
Selective
GH axis
Raun et al., 1998
~2 h
Half-life
Johansen et al., 1999
Tolerable
Phase II POI
Beck et al., 2014
Longitudinal growth
Growth-plate models show dose-responsive gains versus control, approaching recombinant GH-like growth velocities in some reports.
- Control~42 µm/day
- Ipamorelin (high)~52 µm/day
- Delta↑ ~24%
Andersen et al., 2001
Lean mass & recovery
Review literature links pulsatile GH secretagogues to anabolic signaling; bars are illustrative review scales, not ipamorelin-specific RCT endpoints.
Sigalos & Pastuszak, 2018
Slow-wave sleep
Evening secretagogue dosing is discussed alongside slow-wave sleep amplification and nocturnal GH physiology—effect sizes depend on population and staging methods.
Slow-wave sleep duration
Framed as aligning with natural GH surges during deep sleep.
Sigalos & Pastuszak, 2018
Post-operative ileus research
Hypothesis: ghrelin-family prokinetic biology may translate to faster bowel recovery after abdominal surgery—Phase II data primarily addressed safety rather than definitive efficacy claims.
- Trial size117 patients
- Dose0.03 mg/kg BID
- Duration7 days
- TolerabilitySimilar to placebo
Beck et al., 2014
Safety profile from research
Clinical + preclinical reporting
Defining feature remains pituitary-preferential GH release without the cortisol / prolactin noise of early GHRP chemotypes at comparable GH doses.
Commonly cited mild events
Injection site
MildFlushing
MildHeadache
MildDizziness
MildNausea
MildCompared with GHRP-6-class peptides, ipamorelin minimizes:
- Cortisol / stress-axis activation
- ACTH-driven adrenal stimulation
- Prolactin-linked effects
- Aldosterone / fluid retention narratives
AE rates (Phase II POI)
- Ipamorelin 0.03 mg/kg BID87.5%
- Placebo94.8%
- No ipamorelin-attributed serious AE pattern in the public Phase II summary.
- No withdrawal syndrome described on stop.
- Context: perioperative population inflates benign AE noise.
- WADA class S0 — prohibited in sport.
- No FDA-approved therapeutic product; research/lab use only where permitted.
Storage handling reference
Peptide handling
Cold
Lyophilized: refrigerate/freeze per COA.
Reconstitution
Sterile water/buffer; SC typical.
Light
Minimize UV during prep.
Aliquot
Avoid repeat freeze-thaw.
Researcher notes
- Selectivity is dose- and assay-dependent—always cite the exact species, route, and comparator GHRP.
- POI Phase II establishes tolerability more than efficacy; bowel outcomes need dedicated efficacy trials.
- Pulsatile secretagogue kinetics are often argued to be more physiologic than depot GH formulations.
- Compliance: treat as controlled/research material; sport bans apply even if locally legal to possess.
Important Research Notice
Not for human consumption. This product and all products are sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from journals and official publications but should be fact checked. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations and you do not intend to use it for human consumption.